Thieler Law Corp advises investors with losses exceeding $100,000 of the September 4, 2015 lead plaintiff deadline in a class action lawsuit filed against CorMedix Inc (NYSEMKT: CRMD) (“CorMedix” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased CorMedix securities between March 12, 2011 and June 29, 2015, have until September 4, 2015 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased CorMedix securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 866-6157 or emailing mail@thielerlaw.com .  No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that CorMedix’s announcements were materially false and misleading regarding its partnership discussions and imminent Phase 3 trials for its sole product, Neutrolin, that the reported clinical studies on Neutrolin’s effectiveness were misleading and overstated along with overstating the cost effectiveness of Neutrolin as well as overstating the  market claims for Neutrolin, that the Company used paid stock promoters, yet failed to disclose the use of such promoters in its regulatory filings pursuant to Section 17(b) of the Securities Act of 1933. Finally, the complaint alleges that CorMedix insiders enriched themselves at the expense of shareholders by selling stock at inflated prices.

CorMedix Inc (NYSEMKT: CRMD) stock grew from $1.33 per share in December 2014 to as high as $9.87 per share in April 2015.

Then on June 29, 2015,there was a report released about CorMedix Inc that asserted, among other things, that CorMedix Inc is based on a 1970s-era catheter product acquired for less than $1 million in a bankruptcy sale, apparently after at least two failed sales processes, that CorMedix’s market size claims are greatly exaggerated, and that CorMedix Inc is touting misleading clinical-data, as in-depth industry research shows its Neutrolin/Taurolidine product is a failure and “40% benefit!” versus industry standards is inaccurate.

CorMedix Inc (NYSEMKT: CRMD) stock declined $0.81 per share to close at $4.05 per share on June 29, 2015, a drop of over 16.6%, after the release of the report.

If you were negatively impacted by your investment in CorMedix securities between March 12, 2011 and June 29, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185